<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1443">
  <stage>Registered</stage>
  <submitdate>4/07/2006</submitdate>
  <approvaldate>10/07/2006</approvaldate>
  <actrnumber>ACTRN12606000291583</actrnumber>
  <trial_identification>
    <studytitle>Maxi-Analgesic Study</studytitle>
    <scientifictitle>Maxi-Analgesic Study. A prospective, parallel group, double-blind comparison of the analgesic effect of a combination of paracetamol and ibuprofen, paracetamol alone or ibuprofen alone in patients with post-operative pain.</scientifictitle>
    <utrn />
    <trialacronym>Nil</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Post-operative Analgesia</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Post-operative analgesia with Oral Maxigesic (paracetamol 1g + Ibuprofen 300mg) four times a day for 48 hours post-operatively</interventions>
    <comparator>Group 1: Oral paracetamol 1g four times a day up to 48 hours post-operatively
Group 2: Ibuprofen 300mg four times a day up to 48 hours post-operatively</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective is to compare the analgesic efficacy measured by 100mm Visual Analgue Scale Area under the Curve measurements (VAS AUC measurements) (resting and on activity) of 3 different analgesic treatment regimens.</outcome>
      <timepoint>These will be taken at rest and on relevant activity.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1) the requirement for rescue analgesia over the study period</outcome>
      <timepoint>Assessed at the end of the study period (24-48 hrs post-op).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2) a categorical global rating by the patients of pain as nil, mild, moderate or severe. </outcome>
      <timepoint>Assessed at the end of the study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3) the total dose of anti-emetic used over the study  period</outcome>
      <timepoint>Assessed at the end of the study period (24-48 hrs post-op).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4) a categorical global rating by the patient of nausea as nil, mild, moderate or severe  for the period of the study.</outcome>
      <timepoint>Assessed at the end of the study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5 ) number of episodes of vomiting over the period of the study</outcome>
      <timepoint>Assessed at the end of the study period (24-48 hrs post-op).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6) a rating of sleep disturbance on a 100 mm Visual Analogue Scale (0 worst, 100 best) for the study period. </outcome>
      <timepoint>Assessed after each night during the study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>7) a categorical rating of the experience of taking part in the study (as very positive, positive, neutral, negative, and very negative with the opportunity for free comments. </outcome>
      <timepoint>Assessed at the end of the study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8) Correlation of drug serum concentrations and pain scores for patients in oral surgery General Anaesthetic groups using computer statistical modelling</outcome>
      <timepoint>one plasma sample 30 minutes after first dose, then 1-2 further samples when the patient has progressed to the recovery room post-op or the hospital ward</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Undergoing oral surgery (including extraction of at least one lower 8th molar tooth under local or general anaesthetic).</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Consent: Patient declinedStudy contra-indications: Too young (&lt; 16 years) Other Non-steroidal anti-inflammatory drug (NSAID) (other than aspirin = 150mg mg/day) or opioid within 24 hours prior to operation Treatment within 12 hours with other paracetamol or paracetamol containing medicines (e.g. cold treatments)  Pregnant or possibly pregnant Breastfeeding Neurological disorder relating to pain perception History of drug addiction Currently on another experimental agent Weight &lt; 50kg Belief by the clinician that participation in the study may compromise the patient NSAID and/or paracetamol contra-indications: Hypersensitive to aspirin or other NSAID Hypersensitive to paracetamol Severe known haemopoetic, renal* or hepatic disease GI ulcer, severe asthma, allergy etc Currently on ACE inhibitor, warfarin, steroid (other than dexamethasone intra-operatively)**, cyclosporin, tacrolimus, methotrexate Severe local infection. Immunosuppressed.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Double-blinded trial medicines. Allocation is concealed by sealed opaque enevelopes. The person determining if the patient is elegible for inclusion, the surgeon and the study nurse are unaware of the treatment group</concealment>
    <sequence>Randomised into treatment blocks. Simple randomisation by using a randomization table created by computer software (i.e., computerised sequence generation). Stratification is used to allocate patients to either local anaesthetic of general anaesthetic groups and also to study centre</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AFT Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress>Level 2, 9 Anzac ST, Takapuna, Auckland, NEW ZEALAND</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>NZTE &amp; AFT Pharmaceuticals</fundingname>
      <fundingaddress>Level 2, 9 Anzac St, Takapuna, NEW ZEALAND</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>NZTE</sponsorname>
      <sponsoraddress>Level 11, ANZ Centre, 23-29 Albert St, Auckland, NZ</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Measurement of relative differences in post-operative analgesia with 3 different treatments assessed by measurement of reduction in visual analogue scales AUC measurements. Investigators and patients are blinded until after the study is completed, the study database loaded and verified.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mercy Hospital</ethicname>
      <ethicaddress>Mountain Rd, Epsom, Auckland</ethicaddress>
      <ethicapprovaldate>12/11/2004</ethicapprovaldate>
      <hrec>AKX/04/10/298</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Greenlane Hospital</ethicname>
      <ethicaddress>Greenlane, Auckland</ethicaddress>
      <ethicapprovaldate>12/11/2004</ethicapprovaldate>
      <hrec>AKX/04/10/298</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Quay Park Surgical Centre</ethicname>
      <ethicaddress>Parnell, Auckland</ethicaddress>
      <ethicapprovaldate>13/12/2005</ethicapprovaldate>
      <hrec>AKX/04/10/298</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Alan Merry</name>
      <address>Professor and Head of Department
Department of Anaesthesiology
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+649-623 6833 ext. 28443</phone>
      <fax>(64 9) 3737970</fax>
      <email>a.merry@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Hartley ATkinson</name>
      <address>Level 2, 9 Anzac St, Takapuna, Auckland</address>
      <phone>+6494880232</phone>
      <fax>+6494880234</fax>
      <email>hartley@aftpharm.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>